Financial Performance - The company's operating revenue for Q1 2023 was ¥1,532,479,010.19, representing a year-on-year increase of 52.69%[4] - The net profit attributable to shareholders for Q1 2023 was ¥254,149,498.07, reflecting a growth of 60.87% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥238,212,167.05, which is an increase of 80.97% year-on-year[4] - The basic earnings per share for Q1 2023 was ¥0.2698, up by 60.88% from the previous year[4] - The weighted average return on equity increased by 1.30 percentage points to 3.52%[4] - The net profit attributable to shareholders increased by 60.87% year-over-year, driven by market environment changes and expanded sales scale[28] - The company reported a 52.69% increase in operating revenue compared to the previous year[28] - Total revenue for Q1 2023 reached ¥1,533,841,569.17, a significant increase from ¥1,004,694,007.42 in Q1 2022, representing a growth of approximately 52.6%[37] - The net profit for the current period is 254,567,799.24, compared to 157,909,349.25 in the previous period, representing an increase of approximately 61.2%[38] - The total profit amount is 299,979,137.44, up from 188,867,728.87, indicating a growth of about 58.8%[38] - The operating profit for the current period is 299,752,876.23, compared to 188,880,551.48 in the previous period, reflecting an increase of approximately 58.5%[38] - The basic earnings per share is 0.27, compared to 0.17 in the previous period, showing a growth of 58.8%[47] - The company has a total comprehensive income of 254,567,799.24, compared to 157,909,349.25 in the previous period, reflecting an increase of approximately 61.2%[38] Cash Flow and Assets - The net cash flow from operating activities was negative at -¥153,277,856.55, a decline of 298.49% compared to the same period last year[4] - The company's cash and cash equivalents as of March 31, 2023, were ¥839,392,400.29, down from ¥1,001,392,531.66 at the end of 2022[13] - The cash and cash equivalents at the end of the period decreased to 824,842,855.30 RMB from 1,500,174,546.91 RMB at the end of the previous year[20] - Total assets increased by 3.42% year-over-year, reaching 12,075,103,088.03 RMB[26] - The company's total assets increased to ¥12,075,103,088.03 from ¥11,675,475,538.98, marking a rise of about 3.4%[35] - The total liabilities increased to ¥4,714,056,865.82 from ¥4,568,623,170.29, reflecting a rise of approximately 3.2%[36] - Current liabilities decreased to ¥3,454,888,708.77 from ¥3,866,737,710.44, showing a reduction of approximately 10.7%[36] - Long-term borrowings rose significantly to ¥1,020,000,000.00 from ¥460,000,000.00, indicating an increase of approximately 121.7%[36] - The total equity attributable to shareholders increased by 3.58% year-over-year, amounting to 7,352,710,673.96 RMB[26] - The total equity attributable to shareholders increased to ¥7,352,710,673.96 from ¥7,098,917,047.88, representing a growth of about 3.6%[36] Expenses and Investments - Total operating costs for Q1 2023 were ¥1,225,023,970.30, up from ¥851,272,779.55 in Q1 2022, indicating an increase of about 44%[37] - Research and development expenses for Q1 2023 amounted to ¥14,040,635.04, compared to ¥11,020,378.79 in Q1 2022, reflecting a growth of approximately 27.3%[37] - Cash flow from investment activities showed a net inflow of 18,843,359.75 RMB, recovering from a net outflow of -75,155,946.82 RMB in the previous year[20] Shareholder Activities - The company repurchased 2,559,700 shares, accounting for 0.27% of the total share capital, with a total expenditure of 29,991,325.30 RMB[33] - The company raised 1,205,000,000.00 RMB through financing activities, significantly up from 430,000,000.00 RMB in the same period last year[20] Impairment and Losses - The company reported a credit impairment loss of -30,166,769.26, compared to -5,570,740.66 in the previous period, which is a significant increase in losses[38] - The company recorded an asset impairment loss of 528,581.20, a decrease from -10,114,879.31 in the previous period, indicating improved asset performance[38] Other Information - The company reported non-recurring gains of ¥15,937,331.02 after tax for the reporting period[7] - The company reported a net profit margin improvement, with net income for Q1 2023 showing a positive trend compared to the previous year, although specific figures were not disclosed[37] - The company is focusing on market expansion and new product development, as indicated by the increase in sales and R&D expenses[37] - The company has not applied new accounting standards or interpretations for the current period[50]

R&D and Innovation - The company plans to complete the reserve of 40-50 drug varieties annually and initiate at least 6 self-developed generic drug projects[2] - The company has established a tiered R&D product sequence to ensure continuous market competitiveness by systematically applying for new drug varieties[2] - The company's R&D system continued to introduce high-level talents in 2022, optimizing the self-developed expert team and advancing the development of generic and innovative drug projects through international collaborations[109] - Completed registration and submission for 11 generic drug projects, with 11 receiving acceptance notices, including the FDA submission for Tofacitinib Citrate Tablets, a dual China-US project[191] - Initiated Phase I clinical trials for the anti-tumor innovative drug ZBD1006, with 5 dose escalation groups completed[191] - Increased R&D expenses by 28.46% to 709.48 million yuan compared to the previous year[200] - The company is actively expanding international cooperation to introduce innovative and generic drug projects that align with its strategic direction[193] - The company is exploring collaborations with multinational pharmaceutical companies, biotech firms, and academic institutions to develop innovative drugs[193] Quality Control and Safety - The company has implemented a dual-constraint system of "physical and chemical indicators + brand indicators" to ensure the quality and stability of raw materials[4] - The company has developed an online monitoring system for the extraction process and a network chromatography instrument detection system to enhance quality control[4] - The company has established a drug safety monitoring and re-evaluation system to ensure the safety of drugs throughout their lifecycle[4] Financial Performance and Dividends - The total remuneration for directors, supervisors, and senior management in the reporting period was 5.7856 million yuan[21] - The company's cash dividend for 2022 is RMB 26,303,308.98, with a dividend payout ratio of 14.19% of the net profit attributable to ordinary shareholders[29] - The total dividend amount, including cash dividends and share repurchases, is RMB 56,294,634.28, accounting for 30.37% of the net profit attributable to ordinary shareholders[29] - The company plans to distribute a cash dividend of 0.28 yuan per 10 shares, totaling 26,303,308.98 yuan[137] - Total cash dividends, including share repurchases, amount to 56,294,634.28 yuan, representing 30.37% of net profit attributable to shareholders[137] Environmental Protection and Compliance - The company's environmental protection investment in 2022 amounted to RMB 1,456.26 million[50] - The company's wastewater and exhaust emissions comply with national standards, with regular third-party testing conducted[36][52][58][59] - The company has established a comprehensive environmental protection management system, including waste management and emergency response plans[55][56] - The company's internal control system is effective, with an unqualified opinion from the audit firm[32][49] Market Performance and Sales - The company's blood stasis injection product saw a price adjustment from "limited to secondary and above medical institutions for stroke paralysis or central retinal vein occlusion patients" to "limited to secondary and above medical institutions"[70] - The company's bone and muscle system disease treatment segment generated revenue of 602.244 million yuan, with a gross profit margin of 75.34%, but revenue decreased by 27.56% year-over-year[71] - The company's traditional Chinese medicine products ranked first in hospital market share, with a year-over-year sales growth of 3.3% in the fourth quarter of 2022[85] - The company's anti-tumor and immunomodulator products ranked second in hospital market share, with a year-over-year sales decline of 1.9% in the fourth quarter of 2022[85] - The company's systemic anti-infective drugs ranked third in hospital market share, with a year-over-year sales decline of 2.1% in the fourth quarter of 2022[85] - The company's digestive and metabolic drugs ranked fourth in hospital market share, with a year-over-year sales decline of 5.6% in the fourth quarter of 2022[85] - The company's blood stasis injection product (200mg) had a procurement volume of 1.769 million units, with a price range of 20.08 to 28 yuan per unit[71] - The company's blood stasis injection product (100mg) had a procurement volume of 2.089 million units, with a price range of 27.96 to 48.2 yuan per unit[71] - The company's blood stasis capsule product had a procurement volume of 12.938 million units, with a price range of 1.5922 to 1.6642 yuan per unit[71] - Sales of "Zhusheyong Xuesaitong" (injection) increased by 20.70% year-on-year, reaching 2,884.38 million units[173] Corporate Governance and Shareholder Rights - The company has implemented a comprehensive governance structure, ensuring equal rights for all shareholders and transparent decision-making processes[9] - The company has maintained strict compliance with insider information management and disclosure regulations[11] - The company held 8 board meetings in 2022, with 5 conducted via telecommunication and 3 combining on-site and telecommunication methods[41] - The company's dividend policy is in compliance with the company's articles of association and shareholder meeting resolutions, with clear standards and proportions[161] Financial Metrics and Cash Flow - The company's basic earnings per share (EPS) decreased by 48.74% year-over-year to 0.1969 yuan in 2022[99] - The company's diluted EPS also decreased by 48.74% year-over-year to 0.1969 yuan in 2022[99] - The weighted average return on equity (ROE) decreased by 3.04 percentage points to 2.62% in 2022[99] - The company's industrial revenue reached 234,111.89 million yuan, with a pharmaceutical industrial gross margin of 65.34%[108] - The overall gross margin of the company was 59.44% in 2022[108] - The company's sales of cardiovascular and cerebrovascular drugs increased by 74.13% year-over-year to 72,869.97 million yuan[108] - Q1 2022 revenue was RMB 1,003,658,954.36, Q2 revenue was RMB 1,474,995,212.74, Q3 revenue was RMB 837,929,544.71, and Q4 revenue was RMB 897,565,147.91[115] - Net profit attributable to shareholders in Q1 2022 was RMB 157,983,557.32, Q2 was RMB 81,173,585.54, Q3 was a loss of RMB -85,661,561.06, and Q4 was RMB 31,895,075.33[115] - Net cash flow from operating activities in Q1 2022 was RMB 77,223,705.06, Q2 was a negative RMB -98,605,456.45, Q3 was a negative RMB -5,181,535.20, and Q4 was a negative RMB -300,229,473.94[115] - Revenue for 2022 reached 4,214,148,859.72 yuan, a 2.12% increase compared to 2021[133] - Net cash flow from operating activities was -326,792,760.53 yuan, a 24.69% improvement from the previous year[140] - Net cash flow from investing activities was 283,931,024.95 yuan, a significant 167.40% increase compared to 2021[140] - Net cash flow from financing activities was -418,944,606.70 yuan, a 152.54% decrease from the previous year[140] Inventory and Asset Management - Inventory increased by 37.16% to RMB 1,005,750,391.69 in 2022, mainly due to strategic reserve increases[120] - Intangible assets grew by 265.06% to RMB 764,289,818.20, driven by increased product patent technology[120] - Development expenditure increased by 42.45% to RMB 198,491,520.56, reflecting higher R&D investment[120] - Short-term borrowings surged by 116.67% to RMB 1,301,648,472.23, primarily due to increased short-term credit loans[120] - Contract liabilities rose by 343.27% to RMB 54,886,001.28, mainly due to increased advance payments from customers[120] - Long-term borrowings decreased by 64.35% to RMB 460,000,000.00, as the company repaid long-term loans and reclassified some to short-term liabilities[120] - Monetary funds decreased by 35.44% to 1,001,392,531.66 yuan, mainly due to increased investment in fundraising projects[141] - Accounts receivable increased by 59.58% to 135,397,401.38 yuan, primarily due to increased bill settlements[141] - Restricted monetary funds totaled 19,078,340.09 yuan, mainly due to housing deposits and bank acceptance bill guarantees[143] Talent and Compensation - The company has strengthened its talent strategy by combining internal training with external recruitment, focusing on R&D and marketing talent[7] - The company's board of directors includes Chairman Fang Tonghua, who has been in the position since March 2011, with an annual pre-tax compensation of 2.7074 million yuan[152] - The company's total pre-tax compensation for all directors, supervisors, and senior management in 2022 was 8.2162 million yuan[152] - The company is focusing on improving its salary policies to maintain regional industry leadership and integrating incentive mechanisms with the salary system[156] Accounts Receivable and Bad Debt - Accounts receivable within 1 year amounted to 1,398,279,028.46 yuan, with a bad debt provision ratio of 0.50%[166] - Accounts receivable aged 1 to 2 years totaled 188,415,496.95 yuan, with a bad debt provision ratio of 5.00%[166] - Accounts receivable aged 2 to 3 years were 16,767,435.19 yuan, with a bad debt provision ratio of 20.00%[166] - Total accounts receivable stood at 1,606,977,800.91 yuan, with a total bad debt provision of 23,281,498.74 yuan[166] Industry Trends and Market Analysis - MAT sales of multinational companies in China decreased by 4.3% year-over-year in 2022, while domestic companies saw a smaller decline of 1.3%[89] - The Chinese pharmaceutical market is expected to grow at a rate of 7-8% in terms of actual drug sales volume, driven by innovation drugs and influenced by healthcare cost control and volume-based procurement[90] - In 2022, the National Medical Products Administration approved 51 new drugs, including 7 traditional Chinese medicine (TCM) new drugs[90] - Innovation drugs accounted for 25% of the total hospital drug sales in China in 2021, up 5 percentage points from 2017, with domestic innovation drugs increasing their share from 17% to 23%[90] Product and Market Share - The company has 65 products in the 2022 national medical insurance catalog, including 34 Class A and 31 Class B products, with 2 products having adjusted medical insurance notes compared to 2021[68] - The top five customers accounted for 16.44% of total annual sales, with no related party sales[176] - The top five suppliers accounted for 8.37% of total annual purchases, with no related party purchases[177] - The company has 160 R&D personnel, accounting for 5.8% of the total workforce[179] Expenses and Costs - Sales expenses decreased by 5.62% to 608.31 million yuan year-on-year[200] - Management expenses slightly decreased by 0.86% to 321.99 million yuan[200] - Financial expenses decreased by 5.04% to 135.32 million yuan[200] - Revenue from Chinese herbal medicine trade increased by 28.16%, while costs rose by 32.53% due to seasonal and regional price fluctuations[172] Government Subsidies and Other Receivables - The company has a policy for handling government subsidies, where any confirmed subsidies that need to be returned will offset the relevant deferred income balance, with any excess recorded in current profits and losses[163] - Total other receivables amounted to 823.41 million yuan, with government subsidies accounting for 658.84 million yuan[198] Leasing and Asset Recognition - The company recognizes the right to use leased assets as a lessee at the commencement of the lease term, except for simplified short-term leases and low-value asset leases[165] Business Overview and Product Information - The company's main business is in the pharmaceutical manufacturing industry, specifically in the production of traditional Chinese medicine[144] - The product "Injection of Xuesaitong (Freeze-dried)" is used for promoting blood circulation and removing blood stasis, and is classified as a prescription drug and protected traditional Chinese medicine[145] - The company's registered address is in Heilongjiang Province, and its office address is in Harbin, Heilongjiang Province[150]

2022 年第三季度报告 证券代码：603567 证券简称：珍宝岛 黑龙江珍宝岛药业股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是√否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | --- | --- | --- | |-----------------------------|-----------------|---------------------------------------|-------|------------------|--------------------------------------------| | | ...

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 2,478,654,167.10, representing a 52.06% increase compared to CNY 1,630,014,986.26 in the same period last year[19]. - The net profit attributable to shareholders decreased by 13.43% to CNY 239,157,142.86 from CNY 276,272,225.25 year-on-year[19]. - The net cash flow from operating activities improved significantly, with a net outflow of CNY -21,381,751.39, a 94.67% reduction compared to CNY -400,995,833.55 in the previous year[19]. - Basic earnings per share decreased by 21.95% to CNY 0.2539 from CNY 0.3253 in the same period last year[20]. - The weighted average return on net assets fell to 3.34% from 4.90% year-on-year, indicating a decline in profitability[20]. - The company reported a 27.62% increase in net profit after deducting non-recurring gains and losses, reaching CNY 217,546,853.48 compared to CNY 170,459,049.71 in the previous year[19]. - The company reported a non-recurring profit of CNY 21,610,289.38 after accounting for tax effects and minority interests[23]. - The company’s cash and cash equivalents increased slightly to ¥1,553,131,679.12, accounting for 13.13% of total assets, compared to 13.48% in the previous year[79]. - The company’s accounts receivable rose to ¥3,801,089,443.43, representing 32.12% of total assets, up from 29.27% the previous year[79]. - The company’s investment activities generated a net cash flow of ¥215,580,284.33, a significant increase of 255.24% from -¥138,871,309.38 in the previous year[76][77]. Asset Management - The company's total assets increased by 2.84% to CNY 11,832,676,803.40 from CNY 11,506,076,750.01 at the end of the previous year[19]. - The net assets attributable to shareholders increased by 1.98% to CNY 7,182,460,122.18 from CNY 7,042,918,942.75 at the end of the previous year[19]. - The total assets of Harbin Zhenbao Pharmaceutical Co., Ltd. decreased by 4.16% to CNY 1,720,758.1, with a net profit of CNY -41,097,900, a decrease of 381.95% year-on-year[87]. - The total assets of Bozhou Traditional Chinese Medicine Commodity Trading Center Co., Ltd. decreased by 8.44% to CNY 2,137,417.6, while its revenue increased by 70.25% to CNY 772,195,000[88]. - The total current assets amounted to RMB 6,801,540,768.26, compared to RMB 6,676,074,667.39 at the beginning of the period, representing an increase of approximately 1.9%[156]. Research and Development - The company has established a national-level postdoctoral research station and provincial-level technology centers to strengthen its R&D capabilities[54]. - The R&D team consists of nearly 200 members, with over 100 holding doctoral or master's degrees, emphasizing the importance of talent cultivation[54]. - The company is currently developing 3 innovative drug varieties in gynecology, oncology, and digestive metabolism, filling market gaps in traditional Chinese medicine treatment[55]. - The company is actively pursuing innovation in traditional Chinese medicine, with a significant increase in registration applications for innovative traditional Chinese medicines[45]. - The company has developed 49 hospital preparation varieties and is conducting research on 3 registration projects, aiming to modernize and industrialize traditional Chinese medicine[55]. Market Strategy - The increase in operating revenue was primarily due to the expansion of the traditional Chinese medicine business[21]. - The company is focusing on high-demand areas such as cardiovascular and respiratory medications, driven by an aging population and increasing disease prevalence[47]. - The company is expanding its sales channels through the establishment of a comprehensive business system and distribution network, enhancing service quality[34]. - The company has established a comprehensive marketing management service system to enhance service quality and ensure accessibility[62]. - The company has been recognized as one of the top 100 most influential pharmaceutical enterprises in China and ranked 26th in the "Top 100 Chinese Traditional Medicine Enterprises" list[46]. Environmental Responsibility - The company has established a dedicated environmental management organization and appointed a full-time environmental protection officer to enhance its environmental responsibility[112]. - The company’s wastewater discharge complies with the standards set by GB-21906—2008, and it conducts annual third-party testing of its wastewater discharge indicators[114]. - The company’s air emissions from its biomass boilers meet the GB37823-2019 standards, with annual third-party testing conducted for compliance[115]. - The company has achieved a zero discharge of hazardous waste by maintaining strict records of generation and storage processes[127]. - The company’s solid waste is managed by municipal sanitation departments, while hazardous waste is transferred to qualified disposal companies[121]. Corporate Governance - The company has not faced any penalties or corrective actions related to legal violations during the reporting period[135]. - The company has not disclosed any new products or technologies in the current report[135]. - The company did not propose any profit distribution or capital reserve transfer plans for the first half of 2022, with no dividends or stock bonuses planned[108]. - The company has engaged in poverty alleviation efforts, providing support to four households in need with慰问品 valued at 2,194 yuan in the first half of 2022[130]. - The company has committed to not engaging in competitive activities with its subsidiaries, ensuring a focus on mutual benefits[132]. Shareholder Information - The total number of shares after the recent changes is 941,963,592, with 100% being tradable shares[143]. - The largest shareholder, Heilongjiang Chuangda Group Co., Ltd., holds 61.56% of the shares, totaling 579,885,300 shares[148]. - The company has a total of 92,803,592 restricted shares that were released for trading on May 11, 2022[145]. - The company completed a non-public offering of 92,803,592 shares, increasing the total share capital from 849,160,000 to 941,963,592 shares[144]. - The company has not reported any changes in earnings per share or net asset per share due to share changes during the reporting period[144].

Financial Performance - The company's operating revenue for 2021 was RMB 4,126,813,896.18, representing a 21.24% increase compared to RMB 3,403,747,280.97 in 2020[21]. - The net profit attributable to shareholders of the listed company decreased by 23.88% to RMB 332,099,672.96 from RMB 436,285,785.59 in the previous year[21]. - The net profit after deducting non-recurring gains and losses was RMB 79,236,536.87, a significant decrease of 77.92% compared to RMB 358,933,556.59 in 2020[21]. - The net cash flow from operating activities was negative at RMB -433,936,940.94, a decline of 379.64% from RMB 155,178,025.16 in the previous year[21]. - Basic earnings per share decreased by 25.24% to 0.3841 RMB compared to 2020[24]. - The weighted average return on equity dropped to 5.664% from 8.15% in 2020, a decrease of 2.49 percentage points[24]. - The total assets at the end of 2021 were RMB 11,506,076,750.01, an increase of 12.43% from RMB 10,234,312,842.17 at the end of 2020[21]. - The net assets attributable to shareholders of the listed company increased by 28.18% to RMB 7,042,918,942.75 from RMB 5,494,448,424.79 in 2020[21]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of RMB 1.06 per 10 shares, totaling RMB 99,848,140.76[6]. - The company has not proposed any stock bonus or capital reserve transfer to increase share capital for the 2021 fiscal year[6]. Market Position and Strategy - The company has been recognized as the 26th in the "Top 100 Chinese Traditional Medicine Enterprises" list, highlighting its market position[46]. - The company is focusing on optimizing production capacity and product structure to adapt to the new drug procurement environment[40]. - The company plans to implement a market development strategy that includes "self-operated + all-channel + all-terminal" approaches[40]. - The company is actively responding to the new centralized procurement policies for traditional Chinese medicine, developing differentiated competitive strategies[47]. Research and Development - The company has established a comprehensive R&D system with over 200 professionals, focusing on seven major R&D platforms[53]. - The company has shifted its R&D focus from generic drugs to innovative drugs, particularly in the antiviral and anti-tumor fields[136]. - The company has several ongoing clinical trials, including innovative drugs ZBD1042 and HZB1006, both currently in Phase I[162]. - The company has introduced a significant number of high-level talents in the R&D field, enhancing its overall R&D capabilities[161]. Sales and Marketing - The company has optimized its marketing strategies, enhancing its sales management system to cover all levels of medical institutions and retail markets across 32 provinces[79]. - The company is focusing on expanding its retail market presence through a comprehensive sales network[172]. - The company is implementing a refined marketing strategy combining precise招商管理 and自主营销, focusing on both high-level hospitals and grassroots medical markets to expand its retail channels, particularly targeting chain pharmacies[195]. Operational Efficiency - The company has implemented advanced management practices, including a digitalized supply chain system, to improve efficiency and reduce errors in production[84]. - The company is enhancing its sales capabilities by optimizing product lines and expanding retail terminal sales networks[64]. - The company is leveraging data analysis to predict market trends and optimize inventory management for its traditional Chinese medicine trading business[65]. Financial Management and Investments - The company has initiated a strategic partnership with Deloitte to enhance its financial management capabilities through the implementation of an integrated financial system[43]. - The company successfully raised 1.238 billion CNY through a non-public stock issuance, enhancing its strategic operational layout and expanding production capacity[58]. - The company has increased its investment in equity instruments by 44.20%, reaching 591,200,000.00 CNY[141]. Challenges and Risks - The company faces significant risks from frequent pharmaceutical policy changes, including the requirement for public medical institutions to procure 90% of drugs through provincial centralized procurement platforms, impacting the profitability of generic drugs[198]. - The introduction of supportive policies for traditional Chinese medicine aims to promote sustainable development in the industry, marking a new historical development period[199].

证券代码：603567 证券简称：珍宝岛 公告编号：临 2022-040 黑龙江珍宝岛药业股份有限公司 关于参加"2022 年投资者网上集体接待日活动 暨业绩说明会"的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为进一步加强与投资者的互动交流，黑龙江珍宝岛药业股份有限公司（以 下简称"公司"）将参加由黑龙江省上市公司协会联合深圳市全景网络有限公司 共同举办的"黑龙江省上市公司 2022 年度投资者网上集体接待日活动暨业绩说 明会"，现将有关事项公告如下： 为促进上市公司规范运作、健康发展，增强上市公司信息透明度，加强与广 大投资者沟通交流，进一步提升投资者关系管理水平，黑龙江省上市公司协会联 合深圳市全景网络有限公司，在"全景路演"举办"黑龙江省上市公司 2022 年 投资者网上集体接待日活动暨业绩说明会"。投资者可以登陆"全景路演"网站 （https://rs.p5w.net/html/132395.shtml）参与公司本次投资者集体接待日活 动,时间为 2022 年 5 月 12 日（周四）14:30 至 ...

Financial Performance - The company's operating revenue for 2021 was RMB 4,126,813,896.18, representing a 21.24% increase compared to RMB 3,403,747,280.97 in 2020[21]. - The net profit attributable to shareholders of the listed company was RMB 332,099,672.96, a decrease of 23.88% from RMB 436,285,785.59 in the previous year[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 79,236,536.87, down 77.92% from RMB 358,933,556.59 in 2020[21]. - The net cash flow from operating activities was negative at RMB -433,936,940.94, a decline of 379.64% compared to RMB 155,178,025.16 in 2020[21]. - The total assets at the end of 2021 were RMB 11,506,076,750.01, an increase of 12.43% from RMB 10,234,312,842.17 at the end of 2020[21]. - The net assets attributable to shareholders of the listed company increased by 28.18% to RMB 7,042,918,942.75 from RMB 5,494,448,424.79 at the end of 2020[21]. - Basic earnings per share decreased by 25.24% to 0.3841 RMB compared to 2020[24]. - The weighted average return on equity dropped to 5.664% from 8.15% in 2020, a decrease of 2.49 percentage points[24]. - The gross profit margin for the overall business decreased by 22.99 percentage points to 33.75% due to rising costs[106]. - The company achieved a revenue of 4.127 billion RMB, representing a year-on-year growth of 21.24%[98]. Cash Flow and Investments - The company reported a significant increase in cash flow from financing activities, which rose by 173.00% to approximately ¥797.46 million from ¥292.11 million, mainly due to increased funds raised from a private placement[104]. - The company’s cash and cash equivalents at the end of the reporting period totaled approximately ¥107.05 million, primarily restricted due to bank guarantees[133]. - The company reported a significant increase in long-term equity investments, reaching approximately ¥644.88 million, a 43.42% increase compared to the previous period[130]. - The company's debt investments rose to approximately ¥198.08 million, reflecting a 41.41% increase due to increased promotional expenses[130]. - The company experienced a substantial increase in development expenditures, amounting to approximately ¥139.34 million, which is an increase of 182.86% compared to the previous period, attributed to increased capitalized R&D expenses[130]. Research and Development - The company established a comprehensive R&D system with over 200 personnel and seven major R&D platforms, focusing on both traditional Chinese medicine and chemical drugs[53]. - The company has 41 ongoing projects in raw materials and generic drug formulations, aiming to enhance product competitiveness in major therapeutic areas[53]. - The company is focusing on innovative drug research and development, expanding its specialized R&D team, and enhancing overall R&D capabilities[150]. - The company has several ongoing R&D projects, including innovative drugs targeting severe influenza and liver cancer, currently in Phase I clinical trials[151]. - The company’s R&D investment in the "Anti-Influenza Virus New Drug" project was 1,666.57 million RMB, with a significant decrease of 51.65% compared to the previous year[159]. - The company’s R&D investment in the "Pan FGFR Kinase Inhibitor" project was 273.56 million RMB, reflecting a decrease of 53.27% compared to the previous year[159]. - The company is focusing on developing traditional Chinese medicine (TCM) and high-end formulations in chemical and biological drugs, with a strategic shift from product advantages to therapeutic domain advantages[180]. - The company aims to enhance its product pipeline by focusing on cardiovascular, respiratory, orthopedic, oncology, digestive, diabetes, and mental health fields, while also promoting the development of innovative TCM products[181]. Market Strategy and Operations - The company has established a comprehensive marketing network covering the entire country, implementing a "self-operated + all-channel + all-terminal" market development strategy[40]. - The company is focusing on expanding its biopharmaceutical sector, with a new investment cooperation agreement signed for a biopharmaceutical R&D base in Hangzhou[42]. - The company is actively expanding its market presence by optimizing marketing strategies and deepening its service network[76]. - The company is committed to continuous investment in traditional Chinese medicine R&D, collaborating with renowned universities and research institutions to enhance product development[80]. - The company is exploring innovative commercial models, including internet hospitals and logistics solutions, to enhance its service offerings[69]. - The company is focusing on the development of smart factories and intelligent manufacturing to improve production efficiency and product quality[86]. - The company is actively seeking acquisition opportunities to enrich its product pipeline and support steady growth, particularly in overseas markets[181]. - The company emphasizes a three-pronged marketing strategy focusing on academic promotion, market access, and channel development to expand its reach in both high-tier hospitals and grassroots medical markets[184]. Challenges and Risks - The company faced significant procurement cost increases due to rising prices of metals, traditional Chinese medicine materials, and logistics costs influenced by external factors such as the pandemic and environmental policies[192]. - The company is responding to policy changes in the pharmaceutical industry, including the normalization of centralized procurement and the adjustment of medical insurance directories, which significantly impact the market landscape[187]. - The company experienced a 66.43% decline in sales volume for its main product, the injection of blood stasis-removing agent, due to pandemic-related impacts[113]. - The revenue from traditional Chinese medicine preparations decreased by 32.05%, while the gross profit margin fell by 3.23 percentage points, influenced by industry policies and the pandemic[112]. Subsidiaries and Acquisitions - The company established a wholly-owned subsidiary, Zhejiang Suoao Biotechnology Co., Ltd., with a registered capital of RMB 200 million, focusing on technology services and medical research[165]. - The company invested RMB 400 million in Zhejiang Teruisi Pharmaceutical Co., Ltd., acquiring a 16.6665% stake, which increased to 17.0211% due to a shareholder exit[166]. - The company’s subsidiary, Harbin Zhenbao Pharmaceutical Co., Ltd., reported total assets of RMB 1,795.38 million, a decrease of 7.96% from the beginning of the period, with a net profit of RMB 80.09 million, down 69.00% year-on-year[175]. - The company’s subsidiary, Bozhou Chinese Medicine Trading Center Co., Ltd., reported total assets of RMB 2,334.32 million, a decrease of 0.35%, with a net profit of RMB 235.14 million, an increase of 377.45% year-on-year[176].

Financial Performance - The company's revenue for Q1 2022 was CNY 1,003,658,954.36, representing a year-on-year increase of 38.07%[6] - Net profit attributable to shareholders was CNY 157,983,557.32, with a slight increase of 1.72% compared to the same period last year[6] - Total operating revenue for Q1 2022 reached ¥1,004,694,007.42, a significant increase from ¥726,899,141.49 in Q1 2021, representing an increase of approximately 38.2%[29] - Net profit attributable to shareholders of the parent company for Q1 2022 was ¥157,983,557.32, compared to ¥155,310,850.70 in Q1 2021, showing a growth of about 1.1%[32] - The total comprehensive income attributable to the parent company for Q1 2022 was ¥157,983,557.32, an increase from ¥155,310,850.70 in Q1 2021, representing a growth of approximately 1.08%[34] Cash Flow - The net cash flow from operating activities reached CNY 77,223,705.06, showing a significant increase of 121.99% year-on-year[6] - The net cash flow from operating activities for Q1 2022 was ¥77,223,705.06, a significant improvement compared to a negative cash flow of ¥351,162,846.90 in Q1 2021[37] - The total cash inflow from operating activities in Q1 2022 was ¥975,678,578.45, up from ¥660,996,987.02 in the same period last year, indicating a growth of approximately 47.5%[37] - The cash outflow from operating activities in Q1 2022 was ¥898,454,873.39, down from ¥1,012,159,833.92 in Q1 2021, reflecting a decrease of about 11.3%[37] - The net cash flow from financing activities for Q1 2022 was ¥53,986,255.30, a recovery from a negative cash flow of -¥38,018,294.92 in Q1 2021[37] Assets and Liabilities - Total assets at the end of the reporting period were CNY 11,786,477,883.18, an increase of 2.44% from the end of the previous year[9] - Total liabilities increased to ¥4,577,308,066.32 in Q1 2022 from ¥4,454,890,583.10 in Q1 2021, reflecting a rise of approximately 2.8%[29] - The total equity attributable to shareholders of the parent company rose to ¥7,200,999,491.68 in Q1 2022, up from ¥7,042,918,942.75 in Q1 2021, indicating an increase of about 2.2%[29] - The company has a total non-current asset value of ¥4,915,111,671.25, compared to ¥4,830,002,082.62 previously[24] Shareholder Information - Total number of common stock shareholders at the end of the reporting period is 17,850[16] - The largest shareholder, Heilongjiang Chuangda Group Co., Ltd., holds 571,485,300 shares, representing 60.67% of total shares[16] Operating Costs and Expenses - Operating costs for Q1 2022 were ¥851,272,779.55, compared to ¥605,565,649.67 in Q1 2021, marking an increase of approximately 40.5%[29] - Research and development expenses for Q1 2022 were ¥11,020,378.79, slightly down from ¥11,024,356.07 in Q1 2021, indicating a stable R&D investment[30] - The company reported a decrease in sales expenses to ¥110,838,260.50 in Q1 2022 from ¥142,472,135.29 in Q1 2021, a reduction of about 22.3%[30] - The company’s financial expenses decreased to ¥31,977,842.54 in Q1 2022 from ¥34,370,344.56 in Q1 2021, a decline of about 11.6%[30] Investment Income - Investment income surged by 190.02%, attributed to the distribution of profits from associated companies[13] - The total cash inflow from investment activities in Q1 2022 was ¥25,000,849.15, compared to ¥12,815,024.83 in Q1 2021, representing a growth of approximately 95%[37] Other Financial Metrics - Basic earnings per share decreased by 8.3% to CNY 0.1677[6] - The basic and diluted earnings per share for Q1 2022 were both ¥0.17, a slight decrease from ¥0.18 in Q1 2021[34] - The weighted average return on equity was 2.22%, down by 0.56 percentage points compared to the previous year[9] - The company has no significant new product or technology developments reported in the current quarter[19]

证券代码：603567 证券简称：珍宝岛 编号：2022-001 √特定对象调研□分析师会议□媒体采访□业绩说明会 投资者关系活 □新闻发布会□路演活动□现场参观 动类别 □其他（请文字说明其他活动内容） 参与单位名称 上海冰河资本刘春茂、东方阿尔法基金乔海英、长江证券朱学辉、 泰康资产杨磊 及人员姓名 公司领导对公司基本情况做了系统介绍，参会机构与公司相 关领导进行了沟通交流，主要内容如下： 1、中药创新药未来的布局？对公司影响如何？ 答：公司正在布局中药创新药产品，根据不同品种特点做到 投资者关系活动 创新药上市还需要时间。现在有的品种马上进行二期临床，还有 主要内容介绍 的品种在做药学研究，预计明年年底有望拿到批件，还有其他一 些已经立项。其他中药品种的补充也在不断引进有临床和市场价 值的产品，不断补充短线产品和几个大的品种，今年有销售预期。 中药创新药的研发及引进，将会进一步提升公司主营业务产品核 黑龙江珍宝岛药业股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|--------------------------------------- ...

Financial Performance - The company's operating revenue for Q3 2021 was ¥1,072,990,343.47, representing a year-on-year increase of 160.39%[7] - The net profit attributable to shareholders was a loss of ¥33,852,631.99, a decrease of 160.06% compared to the same period last year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥44,698,960.45, with a significant increase of 349.03% year-to-date[7] - The basic and diluted earnings per share were both -¥0.0398, reflecting a decrease of 159.94% year-on-year[9] - Revenue for the period from the beginning of the year to the end of the reporting period was 52.27 million, mainly driven by the growth in traditional Chinese medicine business[14] - Operating costs for the same period reached 137.34 million, also attributed to the increase in traditional Chinese medicine business[14] - The company reported a net profit of CNY 3.24 billion for the first nine months of 2021, up from CNY 2.99 billion in the same period last year[30] - Total operating revenue for the first three quarters of 2021 reached RMB 2,704,740,106.96, a 52.5% increase from RMB 1,780,776,566.44 in the same period of 2020[34] - Operating profit for the third quarter of 2021 was RMB 296,631,230.15, compared to RMB 315,434,418.04 in the third quarter of 2020, reflecting a decrease of 5.5%[36] - Net profit attributable to shareholders of the parent company for the third quarter of 2021 was RMB 242,419,593.26, slightly up from RMB 240,821,172.25 in the same quarter of 2020, indicating a growth of 0.7%[36] Assets and Liabilities - The total assets at the end of the reporting period were ¥10,234,117,571.86, showing a slight decrease of 0.00% compared to the end of the previous year[9] - The equity attributable to shareholders increased to ¥5,737,028,476.17, marking a year-on-year growth of 4.42%[9] - The company reported a significant decrease of 79.83% in cash and cash equivalents at the end of the reporting period, primarily due to payments for herbal medicine and R&D expenses[12] - Inventory increased by 32.49% at the end of the reporting period, mainly due to an increase in herbal materials[12] - Long-term equity investments at the end of the reporting period amounted to 40.89 million, primarily due to increased investment payments to associated companies[14] - The company's total assets amounted to CNY 10.23 billion, with current assets totaling CNY 5.31 billion[24] - Total liabilities were reported at CNY 4.49 billion, a decrease from CNY 4.73 billion year-over-year[30] - The company’s long-term borrowings stood at CNY 2.12 billion, slightly down from CNY 2.13 billion year-over-year[30] - The company’s total non-current assets amounted to CNY 4.92 billion, an increase from CNY 4.23 billion in the previous year[30] - The company’s total liabilities and equity amounted to CNY 10.23 billion, consistent with the total assets reported[33] Cash Flow - The net cash flow from operating activities for the year-to-date was -¥500,324,395.95, indicating a negative cash flow situation[9] - Net cash flow from operating activities for the period was -337.11 million, mainly due to reduced sales collections during the pandemic and increased payments for raw material purchases[14] - Cash flow from investing activities for the period was 46.11 million, primarily due to increased proceeds from the sale of wholly-owned subsidiary equity[14] - Cash flow from financing activities for the period was -157.28 million, mainly due to adjustments in the borrowing structure[14] - Cash received from borrowings was $520,000,000.00, down from $1,940,000,000.00[42] - Cash paid for debt repayment was $569,000,000.00, compared to $1,372,886,295.00 previously[42] - Cash paid for dividends and interest was $108,895,354.71, a decrease from $425,780,138.16[42] - The net increase in cash and cash equivalents was -$1,240,263,192.14, worsening from -$1,022,404,269.05[42] - The ending balance of cash and cash equivalents was $261,597,089.10, significantly lower than $1,483,056,215.26 at the beginning of the period[42] Shareholder Information - The total number of common shareholders at the end of the reporting period was 16,476[14] - The top ten shareholders held a total of 579.89 million shares, representing 68.29% of the total shares[17] Non-Recurring Gains and Expenses - Non-recurring gains included government subsidies amounting to ¥14,088,525.93 for the year-to-date[10] - The company reported a decrease in tax and additional charges to RMB 49,913,584.26 in 2021 from RMB 102,867,926.50 in 2020, a reduction of 51.5%[34] - Research and development expenses for the first three quarters of 2021 were RMB 37,187,830.90, down 22.7% from RMB 48,094,535.80 in the same period of 2020[34] - The company recorded an investment income of RMB 151,656,264.63 for the first three quarters of 2021, down from RMB 240,122,890.14 in the same period of 2020, a decline of 37.0%[34] - The company reported a significant increase in fixed asset disposal income, amounting to 131.96 million, indicating improved asset management[14] Equity Transactions - The company transferred 100% equity of its wholly-owned subsidiaries to Heilongjiang Zhenbao Island Group for a transfer payment of CNY 423 million, representing 53.36% of the total transfer amount[22] Leasing Standards - The company has not applied the new leasing standards since 2021[43]